JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

JNJ

168.27

-0.78%↓

NVS

117.59

+0.37%↑

ABT

126.59

+0.73%↑

MDT

92.9

+0.6%↑

ELV.US

289.29

+3.16%↑

Search

Hutchison China MediTech Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

17.59 -0.79

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

17.59

Max

17.66

Pagrindiniai rodikliai

By Trading Economics

Pajamos

6M

Pardavimai

162M

P/E

Sektoriaus vid.

88.7

38.156

Pelno marža

3.676

Darbuotojai

1,811

EBITDA

-5M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+21.24% upside

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

3B

Ankstesnė atidarymo kaina

18.38

Ankstesnė uždarymo kaina

17.59

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

Hutchison China MediTech Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-07-25 17:53; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750 Million Windfall

2025-07-25 15:58; UTC

Uždarbis
Pagrindinės rinkos jėgos

Aon Shares Rise After 2Q Earnings Beat

2025-07-25 15:08; UTC

Pagrindinės rinkos jėgos

AST SpaceMobile Shares Slide After Convertible Notes, Stock Offerings

2025-07-25 21:40; UTC

Rinkos pokalbiai

Starbucks' Spending Hikes Are Misdirected -- Market Talk

2025-07-25 21:23; UTC

Rinkos pokalbiai

Honeywell's Growth Seen Holding Up Despite Recent Headwinds -- Market Talk

2025-07-25 20:40; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 20:10; UTC

Uždarbis

These Stocks Moved the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 19:56; UTC

Uždarbis

Correction to Why Bargain Hunters Are Flocking to 'Bin Stores' -- Barrons.com on July 20

2025-07-25 19:14; UTC

Rinkos pokalbiai

Oil Futures Post Back-to-Back Weekly Losses -- Market Talk

2025-07-25 19:10; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Appear to Stabilize -- Market Talk

2025-07-25 19:01; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 18:45; UTC

Rinkos pokalbiai

Gold Ends Down Week on Lower Note -- Market Talk

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Sale Could Fetch Around $1B, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH in Talks to Sell Marc Jacobs -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

Suitors for Marc Jacobs Include Authentic, Bluestar Alliance and WHP Global, Sources Say -- WSJ

2025-07-25 18:35; UTC

Įsigijimai, susijungimai, perėmimai

LVMH Exploring Sale of Fashion Brand Marc Jacobs, Sources Say -- WSJ

2025-07-25 17:38; UTC

Pagrindinės rinkos jėgos

Genworth Shares Rise On UK Court Ruling That Could Lead to $750M Windfall

2025-07-25 17:26; UTC

Rinkos pokalbiai

U.S. Oil Rig Count Extends Decline -- Market Talk

2025-07-25 17:13; UTC

Uždarbis

Tesla Stock Is Rising. Robo-taxi Trumps a Lack of New Models. -- Barrons.com

2025-07-25 16:46; UTC

Uždarbis

Volkswagen Teases Made-in-America Audis, Porsches After $1.5 Billion Tariff Hit -- 2nd Update

2025-07-25 16:45; UTC

Uždarbis

Apple Earnings Are Next Week. Why This Analyst Says Be Cautious. -- Barrons.com

2025-07-25 16:27; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Tesla, and More -- Barrons.com

2025-07-25 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-07-25 16:02; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Berkshire Stock Is Losing Its Buffett Premium. Now Is the Time to Buy. -- Barrons.com

2025-07-25 15:34; UTC

Uždarbis

Intel's Harsh Reality Nullifies Tariff Boost -- WSJ

2025-07-25 15:06; UTC

Rinkos pokalbiai

Base Metal Prices Fall on Stronger U.S. Dollar -- Market Talk

2025-07-25 15:05; UTC

Uždarbis

These Stocks Are Moving the Most Today: Intel, Centene, Charter, Newmont, Deckers, Boston Beer, Comfort Systems, and More -- Barrons.com

2025-07-25 14:45; UTC

Rinkos pokalbiai

Oil Rangebound Amid U.S.-EU Trade Uncertainty -- Market Talk

2025-07-25 14:44; UTC

Rinkos pokalbiai

Gold Futures Set to End Week Lower on Easing Trade War Concerns -- Market Talk

2025-07-25 14:36; UTC

Rinkos pokalbiai
Uždarbis

Phillips 66 CEO Says California Administration Supports of LA Plant Closure -- Market Talk

Akcijų palyginimas

Kainos pokytis

Hutchison China MediTech Ltd ADR Prognozė

Kainos tikslas

By TipRanks

21.24% į viršų

12 mėnesių prognozė

Vidutinis 21.35 USD  21.24%

Aukščiausias 28 USD

Žemiausias 14.7 USD

Remiantis 2 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Hutchison China MediTech Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

2 ratings

1

Pirkti

1

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

14.24 / 14.78Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Strong Bearish Evidence

Vidutinės trukmės periodas

Weak Bearish Evidence

Ilgalaikis periodas

Weak Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.